Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07337525 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
A Phase 1 study of Solid Tumor Cancer and Advanced Malignant Solid Tumor, sponsored by Pilatus Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT07337525 is a Phase 1 study of Solid Tumor Cancer and Advanced Malignant Solid Tumor that is actively recruiting participants, run by Pilatus Biosciences. The registered enrollment target is 36 participants, below the 853-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07337525, a Phase 1 study of Solid Tumor Cancer and Advanced Malignant Solid Tumor, is actively recruiting participants, sponsored by Pilatus Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer. The main questions it aims to answer are: What adverse events and toxicities (harmful side effects) are associated with different doses of PLT012? What are the blood levels of PLT012 in your body at different timepoints? What effect does PLT012 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive PLT012 and none will receive placebo (a look-alike substance that contains no drug). Participants will receive PLT012 by intravenous infusion once every 3 weeks. Treatment with PLT012 can continue until the participant's disease worsens or they cannot tolerate treatment. For the first 12 weeks, visits to the clinic will be more frequent (from 1 to 5 times over a 3-week period). After the first 12 weeks, visits will be reduced to once every 3 weeks.
Conditions Studied
Interventions
- DRUG PLT012
Study Locations (2)
Texas
- NEXT Dallas - Dallas
- NEXT Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07337525
The ClinicalTrials.gov registry entry for NCT07337525 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 853-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Pilatus Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor Cancer appearing as the primary indexed condition, and to 1 intervention - of which PLT012 is the first listed.
NCT07337525 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07337525 about?
NCT07337525 is a clinical study titled "A First in Human Study of PLT012 in Participants With Solid Tumor Cancers". The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer. The main questions it aims to answer are: What adverse events and toxiciti...
What is the current status of trial NCT07337525?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-02-13. Estimated completion is 2028-01.
What conditions does trial NCT07337525 study?
This clinical trial studies the following conditions: Solid Tumor Cancer, Advanced Malignant Solid Tumor.
What interventions are being tested in trial NCT07337525?
The interventions under investigation include: PLT012 (DRUG).
Who is sponsoring clinical trial NCT07337525?
This trial is sponsored by Pilatus Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07337525 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RECRUITING · Phase 1
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
COMPLETED · Phase 1
-
SB-743921 In Patients With Solid Tumors
COMPLETED · Phase 1
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.